Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2010 pubmed

Haemophilus ducreyi SapA contributes to cathelicidin resistance and virulence in humans.

Mount. Kristy L B KL; Townsend. Carisa A CA; Rinker. Sherri D SD; Gu. Xiaoping X; Fortney. Kate R KR; Zwickl. Beth W BW; Janowicz. Diane M DM; Spinola. Stanley M SM; Katz. Barry P BP; Bauer. Margaret E ME

Key Findings

  • SapA is produced by H. ducreyi and is conserved across strains
  • SapA specifically protects H. ducreyi from the human peptide LL‑37, but not from other defensins
  • Removing SapA makes the bacteria less able to survive LL‑37 exposure and reduces its disease‑causing ability in humans

Practical Outcomes

  • If you’re considering LL‑37 as a supplement or topical antimicrobial, know that some bacteria have built‑in resistance mechanisms like SapA, which can limit its effectiveness. This research doesn’t change dosing or usage guidelines, but it cautions that LL‑37 may not work against all infections and that bacterial resistance should be considered.

Summary

The study shows that a protein called SapA helps the sexually transmitted bacterium Haemophilus ducreyi survive attacks by the human antimicrobial peptide LL‑37. When SapA is removed, the bacteria become more vulnerable to LL‑37 and cause fewer skin pustules in volunteers. This reveals that LL‑37’s ability to kill some bacteria can be blocked by bacterial defenses.

Abstract

Haemophilus ducreyi is an extracellular pathogen of human epithelial surfaces that resists human antimicrobial peptides (APs). The organism's genome contains homologs of genes sensitive to antimicrobial peptides (sap operon) in nontypeable Haemophilus influenzae. In this study, we characterized the sap-containing loci of H. ducreyi 35000HP and demonstrated that sapA is expressed in broth cultures and H. ducreyi-infected tissue; sapA is also conserved among both class I and class II H. ducreyi strains. We constructed a nonpolar sapA mutant of H. ducreyi 35000HP, designated 35000HPsapA, and compared the percent survival of wild-type 35000HP and 35000HPsapA exposed to several human APs, including alpha-defensins, beta-defensins, and the cathelicidin LL-37. Unlike an H. influenzae sapA mutant, strain 35000HPsapA was not more susceptible to defensins than strain 35000HP was. However, we observed a significant decrease in the survival of strain 35000HPsapA after exposure to LL-37, which was complemented by introducing sapA in trans. Thus, the Sap transporter plays a role in resistance of H. ducreyi to LL-37. We next compared mutant strain 35000HPsapA with strain 35000HP for their ability to cause disease in human volunteers. Although both strains caused papules to form at similar rates, the pustule formation rate at sites inoculated with 35000HPsapA was significantly lower than that of sites inoculated with 35000HP (33.3% versus 66.7%; P = 0.007). Together, these data establish that SapA acts as a virulence factor and as one mechanism for H. ducreyi to resist killing by antimicrobial peptides. To our knowledge, this is the first demonstration that an antimicrobial peptide resistance mechanism contributes to bacterial virulence in humans.

Study Information

Provider

pubmed

Year

2010

Date

2010-01-19T00:00:00.000Z

DOI

10.1128/iai.01014-09